Is It Time To Reassess CONMED (CNMD) After A 39% One Year Share Price Slide

• Investors may be wondering whether CONMED's share price around US$35.94 reflects its true worth, or if the market has pushed it too far in one direction.
• The stock has seen weak recent returns, with a 3.6% decline over the last week, 20.4% over the last month, 11.3% year to date, and 39.3% over the past year. These moves can reshape how investors think about both risk and potential opportunity.
• Recent coverage has focused on CONMED as part of a broader look at medical equipment names, with attention on how market sentiment and sector comparisons tie into the longer term share price performance. This kind of context is important when assessing whether current levels are driven more by sentiment or by fundamentals.
• Despite the share price pressure, CONMED currently holds a valuation score of 6/6. The rest of this article will walk through how different valuation methods arrive at that view, before finishing with a more complete way to think about what the stock might really be worth.

Find out why CONMED's -39.3% return over the last year is lagging behind its peers.

Approach 1: CONMED Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting those back to today using a required rate of return. It is essentially asking what tomorrow’s cash is worth in today’s dollars.

For CONMED, the model starts with last twelve month free cash flow of about $152.5 million. Analysts provide explicit free cash flow estimates for the next few years, and Simply Wall St then extrapolates further projections out to 2035 using its 2 Stage Free Cash Flow to Equity approach. By year ten, projected free cash flow is $221.3 million, all expressed in $ and kept below the 1b mark.

When all those future cash flows are discounted back and combined with the terminal value, the result is an estimated intrinsic value of $88.46 per share. Compared with the recent share price around $35.94, the DCF output suggests the shares trade at about a 59.4% discount. This indicates a wide gap between the market price and this particular intrinsic value estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests CONMED is undervalued by 59.4%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for CONMED.

Approach 2: CONMED Price vs Earnings

For a profitable company like CONMED, the P/E ratio is a useful way to link what you pay for each share to the earnings the business is currently generating. Investors usually expect higher growth or lower perceived risk to justify a higher P/E, while lower growth expectations or higher perceived risk can justify a lower P/E.

CONMED trades on a P/E of 23.6x. That sits below the Medical Equipment industry average of 26.9x and well below the peer group average of 67.5x, which shows a wide range of valuations across the sector. Simply Wall St also calculates a “Fair Ratio” for CONMED of 26.4x, which is the P/E level suggested by factors such as its earnings profile, industry, profit margins, market cap and risk characteristics.

This Fair Ratio is more tailored than a simple comparison with peers or the broad industry, because it adjusts for company specific traits rather than assuming all medical equipment names deserve the same multiple. With CONMED’s actual P/E below the 26.4x Fair Ratio, this approach indicates that the shares may be trading at a discount on an earnings basis.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your CONMED Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, a simple tool on Simply Wall St's Community page that lets you spell out your story for CONMED, link that story to specific forecasts for revenue, earnings and margins, and turn those assumptions into a Fair Value that sits alongside the current price. This Fair Value updates when fresh news or earnings arrive and can differ widely across investors. For example, one CONMED Narrative might lean toward the lower end of analyst outcomes with a Fair Value around US$39, while another leans toward the higher end near US$80. This gives you a clear, numbers based way to see which version of the story you agree with and how that lines up with where the stock trades today.

Do you think there's more to the story for CONMED? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com